AIM: Although CA125 is the most widely used cancer marker in the diagnostic approach of pelvic masses in women, its clinical usefulness is limited because it lacks expression of the antigen in the early stages of disease. The human epididymis protein 4 (HE4) is frequently over-expressed in ovarian cancer, whereas its expression in normal tissues, including the ovary, is low. The aim of this study was to assess the concentration of both HE4 and CA125 in patients with different forms of benign and malign pelvic masses. METHODS: The study population included 99 patients with gynecological cancer (46 ovarian, 39 endometrial, 14 cervical) and 40 affected by benign disease (22 endometriosis and 18 benign ovarian mass). Twelve control subjects were also included in the study. In all the patients, serum samples were collected on the day before scheduled surgery. RESULTS: The median CA125 and HE4 serum levels were significantly higher among ovarian cancer patients as compared with healthy subjects and with those with benign mass, cervical, and endometrial tumors. The receiver operating characteristics curve analysis on healthy controls and patients with ovarian cancers revealed that HE4 had a significantly higher area under the curve when compared with CA125 (0.99 vs. 0.91), with a sensibility and specificity of 98 and 100%, respectively. CONCLUSIONS: HE4 seems to be a promising ovarian cancer marker, and its measurement might improve the diagnostic approach to patients with pelvic masses.
AIM: Although CA125 is the most widely used cancer marker in the diagnostic approach of pelvic masses in women, its clinical usefulness is limited because it lacks expression of the antigen in the early stages of disease. The humanepididymis protein 4 (HE4) is frequently over-expressed in ovarian cancer, whereas its expression in normal tissues, including the ovary, is low. The aim of this study was to assess the concentration of both HE4 and CA125 in patients with different forms of benign and malign pelvic masses. METHODS: The study population included 99 patients with gynecological cancer (46 ovarian, 39 endometrial, 14 cervical) and 40 affected by benign disease (22 endometriosis and 18 benign ovarian mass). Twelve control subjects were also included in the study. In all the patients, serum samples were collected on the day before scheduled surgery. RESULTS: The median CA125 and HE4 serum levels were significantly higher among ovarian cancerpatients as compared with healthy subjects and with those with benign mass, cervical, and endometrial tumors. The receiver operating characteristics curve analysis on healthy controls and patients with ovarian cancers revealed that HE4 had a significantly higher area under the curve when compared with CA125 (0.99 vs. 0.91), with a sensibility and specificity of 98 and 100%, respectively. CONCLUSIONS:HE4 seems to be a promising ovarian cancer marker, and its measurement might improve the diagnostic approach to patients with pelvic masses.
Authors: Gordon J S Rustin; Robert C Bast; Gary J Kelloff; J Carl Barrett; Stephen K Carter; Perry D Nisen; Caroline C Sigman; David R Parkinson; Raymond W Ruddon Journal: Clin Cancer Res Date: 2004-06-01 Impact factor: 12.531
Authors: Ronny Drapkin; Hans Henning von Horsten; Yafang Lin; Samuel C Mok; Christopher P Crum; William R Welch; Jonathan L Hecht Journal: Cancer Res Date: 2005-03-15 Impact factor: 12.701
Authors: Robert C Bast; Molly Brewer; Changping Zou; Mary A Hernandez; Mary Daley; Robert Ozols; Karen Lu; Zhen Lu; Donna Badgwell; Gordon B Mills; Steven Skates; Zhen Zhang; Dan Chan; Anna Lokshin; Yinhua Yu Journal: Recent Results Cancer Res Date: 2007
Authors: Dan Grisaru; Jan Hauspy; Mona Prasad; Monique Albert; K Joan Murphy; Allan Covens; Pascale F Macgregor; Barry Rosen Journal: Oncol Rep Date: 2007-12 Impact factor: 3.906
Authors: Ingegerd Hellström; John Raycraft; Martha Hayden-Ledbetter; Jeffrey A Ledbetter; Michèl Schummer; Martin McIntosh; Charles Drescher; Nicole Urban; Karl Erik Hellström Journal: Cancer Res Date: 2003-07-01 Impact factor: 12.701
Authors: Daniel G Rosen; Lin Wang; J Neeley Atkinson; Yinhua Yu; Karen H Lu; Eleftherios P Diamandis; Ingegerd Hellstrom; Samuel C Mok; Jinsong Liu; Robert C Bast Journal: Gynecol Oncol Date: 2005-08-02 Impact factor: 5.482
Authors: Laura J Havrilesky; Clark M Whitehead; Jennifer M Rubatt; Robert L Cheek; John Groelke; Qin He; Douglas P Malinowski; Timothy J Fischer; Andrew Berchuck Journal: Gynecol Oncol Date: 2008-06-27 Impact factor: 5.482
Authors: Richard G Moore; Amy K Brown; M Craig Miller; Steven Skates; W Jeffrey Allard; Thorsten Verch; Margaret Steinhoff; Geralyn Messerlian; Paul DiSilvestro; C O Granai; Robert C Bast Journal: Gynecol Oncol Date: 2007-12-03 Impact factor: 5.482
Authors: A Oaknin; R Guarch; P Barretina; D Hardisson; A González-Martín; X Matías-Guiu; A Pérez-Fidalgo; B Vieites; I Romero; J Palacios Journal: Clin Transl Oncol Date: 2017-08-16 Impact factor: 3.405
Authors: Rafael Molina; Jose M Escudero; Jose M Augé; Xavier Filella; Laura Foj; Aureli Torné; Jose Lejarcegui; Jaume Pahisa Journal: Tumour Biol Date: 2011-08-24
Authors: Sanjeev K Srivastava; Aamir Ahmad; Haseeb Zubair; Orlandric Miree; Seema Singh; Rodney P Rocconi; Jennifer Scalici; Ajay P Singh Journal: Cancer Lett Date: 2017-05-24 Impact factor: 8.679